Broad-based skin cancer screening may strain healthcare resources and lead to overdiagnosis, but it may also help catch more ...

Regeneron Pharmaceuticals Inc. closed 49.58% below its 52-week high of $1,211.20, which the company achieved on August 27th.

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

The city’s pharma giants avoided much of the initial turbulence felt by the rest of the economy in the wake of President Donald Trump’s sweeping tariffs. The S&P 500 cratered Thursday following news ...

Black Health Matters (BHM), the nation's leading health equity platform dedicated to improving the health outcomes of Black ...

Medical marketers, ad agencies, physicians and pharma executives gathered for MM+M’s annual Transform conference, held at One ...

Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

General Douglas MacArthur High School in the Levittown School District has announced Melody Hong and Katherine Tian as its ...

Pharmaceutical (TADAWUL:2070) stocks saw brief relief Thursday after U.S. President Donald Trump left drug products off the list of newly announced tariffs. However, industry leaders and analysts ...

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...